Tobacco Free initiative | Know the truth | Tobacco and waterpipe use increases the risk of suffering from COVID-19

Tobacco and waterpipe use increases the risk of suffering from COVID-19

Print PDF
Since waterpipe smoking is typically an activity that takes place within groups in public settings and waterpipe use increases the risk of transmission of diseases, it could also encourage the transmission of COVID-19 in social gatherings.

Tobacco and waterpipe users are at increased risk of COVID-19 infection

This Q&A is based on, and benefitted from, the most recent evidence on COVID-19 and tobacco use. Although evidence is still accumulating on the links between COVID-19 and tobacco, waterpipe and e-products use, current research suggests a possible association between smoking and increasing severity of COVID-19 symptoms. Therefore, it is important to raise awareness in this area. There are still research gaps that need to be addressed. As more research data become available, the Q&A will be updated accordingly.

What are the possible relations between tobacco use and the COVID19 pandemic?

Tobacco use may increase the risk of suffering from serious symptoms due to COVID-19 illness. Early research indicates that, compared to non-smokers, having a history of smoking may substantially increase the chance of adverse health outcomes for COVID-19 patients, including being admitted to intensive care, requiring mechanical ventilation and suffering severe health consequences [1] [2].

Smoking is already known to be a risk-factor for many other respiratory infections, including colds, influenza, pneumonia and tuberculosis [3]. The effects of smoking on the respiratory system makes it more likely that smokers contract these diseases, which could be more severe [4] [5]. Smoking is also associated with increased development of acute respiratory distress syndrome, a key complication for severe cases of COVID-19 [6], among people with severe respiratory infections [7] [8].

Any kind of tobacco smoking is harmful to bodily systems, including the cardiovascular and respiratory systems [9] [10]. COVID-19 can also harm these systems. Evidence from China, where COVID-19 originated, shows that people who have cardiovascular and respiratory conditions caused by tobacco use, or otherwise, are at higher risk of developing severe COVID-19 symptoms [11]. Research on 55 924 laboratory confirmed cases show that the crude fatality rate for COVID-19 patients is much higher among those with cardiovascular disease, diabetes, hypertension, chronic respiratory disease or cancer than those with no pre-existing chronic medical conditions [12]. This demonstrates that these pre-existing conditions may increase the vulnerability of such individuals to COVID-19.

Tobacco use has a huge impact on respiratory health and is the most common cause of lung cancer [13]. It is also the most important risk-factor for chronic obstructive pulmonary disease (COPD), which causes the swelling and rupturing of the air sacs in the lungs, reducing the lung’s capacity to take in oxygen and expel carbon dioxide, and the build-up of mucus, resulting in painful coughing and breathing difficulties [14] [15] [16]. This may have implications for smokers given that the virus that causes COVID-19 primarily affects the respiratory system often causing mild to severe respiratory damage [12], which could result in fatality. However, given that COVID-19 is a newly identified disease, the link between tobacco use and the disease needs further documentation and research.

In addition, there is an increased risk of more serious symptoms and death among COVID-19 patients who have underlying conditions, including cardiovascular diseases (CVDs) [17] [18]. The virus that causes COVID-19 (SARS-CoV-2) is from the same family as MERS-CoV and SARS-CoV, both of which have been associated with cardiovascular damage (either acute or chronic) [19] [20]. There is also evidence that COVID-19 patients that have more severe symptoms often have heart-related complications [22]. This relationship between COVID-19 and cardiovascular health is important because tobacco use and exposure to second-hand smoke are major causes of CVDs globally [23]. The effect of COVID-19 on the cardiovascular system could thus make pre-existing cardiovascular conditions worse. Additionally, a weaker cardiovascular system among COVID-19 patients with a history of tobacco use could make such patients more vulnerable to severe symptoms, thereby increasing the risk for those patients [24].

How can use of waterpipe contribute to the spread of COVID19?

The main ingredient used in waterpipe is tobacco, and its use has both acute and long-term harmful effects on the respiratory and cardiovascular systems [25] [26], likely increasing the risk of diseases including coronary artery disease and COPD [27].

The communal nature of waterpipe smoking means that a single mouthpiece and hose are often shared between users, especially in social settings [28]. In addition, the waterpipe apparatus (including the hose and chamber) itself may provide an environment that promotes the survival of microorganisms outside the body. Most cafés tend not to clean the waterpipe equipment, including the water jar, after each smoking session because washing and cleaning waterpipe parts is labour intensive and time consuming [29] [30]. These factors increase the potential for the transmission of infectious diseases between users [26].

Consistent with this, evidence has shown that waterpipe use is associated with an increased risk of transmission of infectious agents, including respiratory viruses, hepatitis C virus, Epstein Barr virus, Herpes Simplex virus, tuberculosis, Heliobacter pylori, and Aspergillus [31] [32] [33] [34] [35] [36].

Social gatherings also provide ample opportunity for the virus that causes COVID-19 to spread [37]. Since waterpipe smoking is typically an activity that takes place within groups in public settings [28], and waterpipe use increases the risk of transmission of diseases, it could also encourage the transmission of COVID-19 in social gatherings. When waterpipe use takes place in indoor areas, as it does in many places, the risk could be higher.

Will strengthened tobacco control measures help in this context?

In 2008, WHO introduced the MPOWER technical package, which is based on the tobacco demand-reduction articles of the WHO Framework Convention on Tobacco Control (WHO FCTC). These measures are as follows:

Monitor tobacco use and prevention policies.

Protect people from tobacco use.

Offer help to quit tobacco use.

Warn about the dangers of tobacco.

Enforce bans on tobacco advertising, promotion and sponsorship.

Raise taxes on tobacco.

Strengthened tobacco control measures, including tobacco-free public places and the protection of people from second-hand smoke as per Article 8 of the WHO FCTC and its Guidelines could reduce the risk of suffering from severe symptoms. Lower rates of tobacco use will reduce rates of many respiratory and cardiovascular conditions that are associated with more serious COVID-19 symptoms and mortality.

Good respiratory and cardiovascular health is important for a COVID-19 patient to positively respond and successfully recover from the disease.

Reducing the demand for tobacco products, including waterpipe products, will discourage the social gatherings associated with these products that contribute to the spread of the virus.

In addition, improved tobacco control could substantially reduce the background demand placed on health systems at this time, allowing more resources to be focused on treating COVID-19 patients. Research shows that the introduction of comprehensive, enforced smoke-free laws around the world was followed by significant reductions in hospital admissions for a wide variety of acute cardiac and respiratory diseases [38].

Specifically regarding waterpipe use, since it is often overlooked in tobacco control efforts, there is a significant opportunity for positive health outcomes at this time, both with respect to COVID-19 and generally, if immediate comprehensive tobacco control measures are taken that include the control of waterpipe.

Countries can use WHO’s highly effective, evidence-based MPOWER policy package to support their formulation and implementation of tobacco control measures to protect public health.

How can regional tobacco control legislation support the limitation of the virus spreading?

The WHO FCTC and the MPOWER policy package apply at both the global level and the regional level within the Eastern Mediterranean Region (EMR). Countries should seek to limit the use of waterpipe and other tobacco use in order to reduce its well documented health impact and improve people’s respiratory and cardiovascular health.

Controlling tobacco use and reducing waterpipe use may be important for reducing the risk of the transmission of the virus that causes COVID-19. It is important that the control of waterpipe use is taken especially seriously at this time and within a comprehensive approach to control all tobacco use, in light of the WHO FCTC obligations and MPOWER recommendations.

In general, WHO recommends that countries fully implement the WHO FCTC and the MPOWER policy package. This includes a comprehensive ban on all forms of tobacco use, including waterpipe use, in all indoor (and, as appropriate, outdoor) public places (including cafes and restaurants). Such a ban may help prevent any increased risk of transmission of the virus that causes COVID-19 related to waterpipe use. Countries are encouraged to ensure that this ban is in place and fully enforced.

Why is this a good time to try and quit tobacco and waterpipe use?

Tobacco use dramatically increases the risk of many serious health problems, including both respiratory problems (like lung cancer, TB and COPD) and CVDs. While this means that it is always a good idea to quit tobacco use, quitting tobacco and waterpipe use may be especially important at this time to reduce the harm caused by COVID-19. The absence of smoking helps reduce touching the mouth with the fingers. Also, it is possible that current smokers would better manage any pre-existing conditions if they do become infected because quitting tobacco use has an almost immediate positive impact on lung and cardiovascular function and these improvements increase as time goes on [3]. Such improvements may increase the ability of COVID-19 patients to respond to the infection and potentially reduce the risk of developing severe symptoms.

What are the key lessons learnt from previous experiences?

From previous experience in responding to MERS-CoV and SARS-CoV, general precautions should be taken, especially in social gatherings [37].

Waterpipes may be a catalyst for social gatherings in environments that could increase disease transmission.

Previous evidence shows that smoking has adverse effects on the survival of individuals with infectious diseases [39]. Evidence from other outbreaks caused by viruses from the same family as COVID-19 suggests that tobacco smoking could, directly or indirectly, contribute to an increased risk of infection, poor prognosis and/or mortality for infectious respiratory diseases [40] [41].

Is it safe to use tobacco including waterpipe at home during the COVID-19 pandemic?

It is not safe to use tobacco at home. Using tobacco at home is associated with the same risks as tobacco use in public places [3]. Tobacco use, including waterpipe use, in any setting is harmful to the health of the user and anyone who breathes in the tobacco smoke.

The home setting is often the place where both children and adults are most exposed to second-hand smoke [42] [43]. Children are especially susceptible to second-hand smoke exposure, which has been shown to increase their risk of lower respiratory tract infections, asthma, middle ear disease and other debilitating health conditions [3]. Children exposed to second-hand smoke are also prone to suffer more severe symptoms of respiratory syncytial infection (like COVID-19, respiratory syncytial infection is a form of viral pneumonia) [44]. There may be an increased danger of second-hand smoke exposure during the COVID-19 pandemic because more people, including smokers and the people they live with, are spending longer periods of time in their homes as part of ‘lockdown measures’ imposed by some countries to reduce disease transmission.

In addition, exposure to third-hand smoke at home might be increased [45]. Third-hand smoke is the persistent residue resulting from tobacco smoke (e.g. from cigarette or waterpipe smoke) that accumulates in dust, objects, and on surfaces in homes where tobacco has been used and is re-emitted into the air [46]. Children are exposed to third-hand smoke toxicants via inhalation, ingestion, and dermal transfer [46] [47].

In response to the COVID-19 pandemic, 15 countries in the Eastern Mediterranean Region have introduced new measures to ban waterpipe use in all public places (while two had already banned its before the pandemic). Despite the ban on use in public places, waterpipe use in the home has persisted. In some instances, people are able to have waterpipe delivered to their homes, facilitating access during the COVID-19 pandemic [48]. It is important to note that waterpipe use at home is harmful to the user, as well as to non-users who breathe in second-hand smoke. The impact of tobacco smoke on respiratory and cardiovascular health, as well as the risk of transmission of infectious agents through shared waterpipe use, are of serious concern during the COVID-19 pandemic.

Why are e-cigarettes not a "safer" alternative during the COVID-19 pandemic and beyond?

Evidence reveals that electronic nicotine delivery systems (ENDS) and electronic non-nicotine delivery systems, more commonly referred to as e-cigarettes, are harmful to health and undoubtedly unsafe. E-cigarette emissions typically contain nicotine and other toxic substances that are harmful to both users and non-users who have been exposed to the aerosols second-hand [50] [51]. The use of e-cigarettes also increases the risk of heart disease and lung disorders [52] [53].

Given the growing evidence that e-cigarette use could be associated with lung injuries and in recent times the link to an outbreak of lung injury in the USA [49] [50] [54], described as ‘e-cigarette or vaping product use associated lung injury’ (EVALI) [55], COVID-19 may have implications for e-cigarette users. This is because the COVID-19 virus affects the respiratory tract. Further, e-cigarette use may suppress immune and inflammatory-response genes in nasal epithelial cells in a similar way to cigarette smoke [56], which may predispose e-cigarette users to COVID-19. The hand-to-mouth action by e-cigarette users may also put them at increased risk of contracting the disease. If e-cigarette devices are shared, the risk of transmission is also likely to be increased. Given that some countries are in lockdown and access to e-cigarettes may be limited, especially for youth, the sharing of devices may be more common under these circumstances.

In addition, the scientific evidence regarding the effectiveness of ENDS as a smoking cessation aid is still being debated. To date, in part due to the diversity of ENDS products and the low certainty surrounding many studies, the potential for ENDS to play a role as a population-level tobacco cessation intervention is unclear. Tobacco users should quit completely and not switch to e-cigarettes, which pose health risks of their own, and are not safe [57]. The safest approach is not to use either tobacco products or e-cigarettes [54]. Using any of these products may increase the risk of COVID-19 patients suffering more severe illness.

Tobacco users who want to quit should use tried and tested interventions such as brief advice from health professionals, and national quit lines or cessation interventions delivered via mobile text message (i.e. m-cessation for tobacco cessation), where available.

What is next?

This document is based on the most updated available evidence. It will be updated as new evidence emerges.

In the context of COVID-19, countries are encouraged to take the needed action to protect the public from the devastating health consequences of tobacco use in light of their international commitments under the WHO FCTC and WHO recommendations.

Additional resources

There are many additional resources related to tobacco, waterpipe and e-cigarette use and COVID-19 that have been published by WHO and other organizations. Here are some key online resources.

Coronavirus (COVID-19): effective options for quitting smoking during the pandemic. London: Cochrane Special Collection; 2020.

Coronavirus update. Washington DC: Action on Smoking and Health; 2020.

COVID-19 and smoking: resources, research and news. London: Tobacco Control (BMJ); 2020.

COVID-19 and tobacco industry interference. Thailand: Global Center for Good Governance in Tobacco Control; 2020.

COVID-19 and tobacco policy and communication toolkit. Washington D.C.: Action on Smoking and Health; 2020.

COVID-19: quit smoking and vaping to protect your lungs. Washington D.C.: Campaign for Tobacco-Free Kids; 2020.

COVID-19: implications for people who smoke or vape. Washington DC: Campaign for Tobacco-Free Kids; 2020.

COVID-19: the connection to smoking and vaping, and resources for quitting. Washington DC: Truth Initiative; 2020.

Increased risk of COVID-19 infection amongst smokers and amongst waterpipe users. Beirut: WHO FCTC Knowledge Hub for Waterpipe Tobacco Smoking; 2020.

Links between smoking and COVID-19. Bath: Stopping Tobacco Organizations and Products (STOP); 2020.

People who are at higher risk of severe illness. Atlanta: U.S. Centres for Disease Control; 2020.

Smoking and COVID-19: factsheet. New York: Vital Strategies; 2020.

Statement on COVID-19 and smoking. Paris: The Union; 2020.

Tobacco control during the COVID-19 pandemic: how we can help. Geneva: WHO FCTC Secretariat; 2020.

Tobacco tactics: COVID-19. Bath: University of Bath Tobacco Control Research Group; 2020.

What do we know about tobacco use and COVID-19? Atlanta: Tobacco Atlas; 2020.

WHO Q&A on smoking and COVID-19. Geneva: World Health Organization; 2020.

WHO statement: tobacco use and COVID-19. Geneva: World Health Organization; 2020.

References and additional information

[1] C. Vardavas and K. Nikitara, “COVID-19 and smoking: A systematic review of the evidence,” Tobacco Induced Diseases, vol. 18, no. 20, 2020.

[2] W. Liu, Z. Tao, W. Lei, Y. Ming-Li, L. Kui, Z. Ling, W. Shuang, D. Yan, L. Jing, H. Liu, Y. Ming and H. Yi, “Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease,” Chinese Medical Journal, 2020.

[3] U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, The health consequences of smoking: 50 years of progress - A report by the Surgeon General, Atlanta, 2014.

[4] S. Murin and K. Bilello, “Respiratory tract infections: Another reason not to smoke,” Cleveland Clinic Journal of Medicine, vol. 72, no. 10, 2005.

[5] K. Lönnroth and M. Raviglione, “Global Epidemiology of Tuberculosis: Prospects for Control,” Seminars in Respiratory and Critical Care Medicine, vol. 29, no. 5, pp. 481-491, 2008.

[6] World Health Organization, Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim Guidance, 2020.

[7] S. Hsieh, H. Zhuo, N. Benowitz, B. Thompson, K. Liu, M. Matthay and C. Calfee, “Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome,” Critical Care Medicine, vol. 42, no. 9, pp. 2058-68, 2014.

[8] C. Calfee, M. Matthay, K. Kangelaris, E. Siew, D. Janz, G. Bernard, A. May, P. Jacob, C. Havel, N. Benowitz and L. Ware, “Cigarette Smoke Exposure and the Acute Respiratory Distress Syndrome,” Critical Care Medicine, vol. 43, no. 9, pp. 1790-7, 2015.

[9] World Health Organization, World Heart Federation, Cardiovascular harms from tobacco use and secondhand smoke: Global gaps in awareness and implications for action, Waterloo, Ontario, Geneva, 2012.

[10] World Health Organization, World No Tobacco Day 2018: Tobacco breaks hearts - choose health. not tobacco, Geneva, 2018.

[11] W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D. Hui, B. Du, L. Li, G. Zeng, K. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang, S. Li, J. Wang, Z. Liang, X. Peng, L. Wei, Y. Liu, Y. Hu, P. Peng, J. Wang, J. Liu, Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu and N. Zhong, “Clinical Characteristics of Coronavirus Disease 2019 in China,” New England Journal of Medicine, 2020.

[12] World Health Organization, Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), 14-20 Februray 2020., 2020.

[13] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394-424, 2018.

[14] N. Terzikhan, K. M. C. Verhamme, A. Hofman, B. H. Stricker, G. G. Brusselle and L. Lahousse, “Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study,” European Journal of Epidemiology, vol. 31, no. 8, pp. 785-792, 2016.

[15] Institute for Health Metrics and Evaluation, “GBD Compare | IHME Viz Hub,” [Online]. Available: http://vizhub.healthdata.org/gbd-compare. [Accessed 12 03 2020].

[16] C. Janson, G. Marks, S. Buist, L. Gnatiuc, T. Gislason, M. A. McBurnie, R. Nielsen, M. Studnicka, B. Toelle, B. Benediktsdottir and P. Burney, “The impact of COPD on health status: findings from the BOLD study,” European Respiratory Journal, vol. 42, no. 6, pp. 1472-1483, 2013.

[17] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang and B. Cao, “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The Lancet, vol. 395, no. 10223, pp. 497-506, 2020.

[18] Y.-Y. Zheng, Y.-T. Ma, J.-Y. Zhang and X. Xie, “COVID-19 and the cardiovascular system,” Nature Reviews Cardiology, 2020.

[19] T. Alhogbani, “Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus,” Annals of Saudi Medicine, vol. 36, no. 1, pp. 78-80, 2016.

[20] Q. Wu, L. Zhou, X. Sun, Z. Yan, C. Hu, J. Wu, L. Xu, X. Li, H. Liu, P. Yin, K. Li, J. Zhao, Y. Li, X. Wang, Y. Li, Q. Zhang, G. Xu and H. Chen, “Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection,” Scientific Reports, vol. 7, no. 1, 2017.

[21] D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, B. Wang, H. Xiang, Z. Cheng, Y. Xiong, Y. Zhao, Y. Li, X. Wang and Z. Peng, “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China,” Journal of the American Medical Association, 2020.

[22] Global Burden of Disease 2018 Risk Factor Collaborators, Institute for Health Metrics and Evaluation, “Global, regional and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis,” The Lancet, 2018.

[23] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020, vol. 2, 2020.

[24] World Health Organization, Factsheet: Waterpipe smoking and health, 2015.

[25] WHO Study Group on Tobacco Product Regulation, Waterpipe tobacco smoking: health effects, research needs and recommended actions for regulators (2nd ed.), 2015.

[26] Z. El-Zaatari, H. Chami and G. Zaatari, “Health effects associated with waterpipe smoking,” Tobacco Control, vol. 24, no. Suppl 1, pp. 31-43, 2015.

[27] W. Maziak, Z. Taleb, R. Bahelah, F. Islam, R. Jaber, R. Auf and R. Salloum, “The global epidemiology of waterpipe smoking,” Tobacco Control, vol. 24, no. Suppl 1, pp. 3-12, 2015.

[28] P. Koul, M. Hajni, M. Sheikh, U. Khan, A. Shah, Y. Khan, A. Ahanger and R. Tasleem, “Hookah smoking and lung cancer in the Kashmir valley of the Indian subcontinent,” Asian Pacific Journal of Cancer Prevention, vol. 12, no. 2, pp. 519-24, 2011.

[29] K. Daniels and N. Roman, “A descriptive study of the perceptions and behaviors of waterpipe use by university students in the Western Cape, South Africa,” Tobacco Induced Diseases, vol. 11, no. 1, 2013.

[30] J. Urkin, R. Ochaion and A. Peleg, “Hubble bubble equals trouble: the hazards of water pipe smoking,” Scientific World Journal, vol. 2, no. 6, pp. 1990-7, 2006.

[31] W. Munckhof, A. Konstantinos , M. Wamsley, M. Mortlock and C. Gilpin, “A cluster of tuberculosis associated with use of marijuana water pipe,” Internation Journal of Tuberculosis and Lung Disease, vol. 7, no. 9, pp. 860-5, 2003.

[32] M. El-Barrawy, M. Morad and M. Gaber, “Role of Helicobacter pylori in the genesis of gastric ulcerations among smokers and nonsmokers,” Eastern Mediterranean Health Journal , no. 3, pp. 316-21, 1997.

[33] M. Habib, M. Mohammed, F. Abdel-Aziz, L. Magder, M. Abdel-Hamid, F. Gamil, S. Madkour, N. Mikhail, W. Anwar, G. Strickland, A. Fix and I. Sallam, “Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity,” Hepatology, vol. 33, no. 1, pp. 248-53, 2001.

[34] B. Knishkowy and Y. Amitai, “Water-pipe (narghile) smoking: an emerging health risk behavior,” Pediatrics, vol. 116, no. 1, pp. 113-9, 2005.

[35] M. Szyper-Kravitz, R. Lang, Y. Manor and M. Lahav, “Early invasive pulmonary aspergillosis in a leukemia patient linked to aspergillus contaminated marijuana smoking,” Leukemia & Lymphoma, vol. 42, no. 6, pp. 1433-7, 2001.

[36] US Centers for Diseases Control and Prevention, Implementation of Mitigation Strategies for Communities with local COVID-19 Transmission, 2020.

[37] C. Tan and S. Glantz, “Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: a meta-analysis,” Circulation, vol. 126, no. 18, pp. 2177-2183, 2012.

[38] R. Huttunen, T. Heikkinen and J. Syrjanen, “Smoking and the outcome of infection,” Journal of Internal Medicine, vol. 269, no. 3, pp. 258-269, 2010.

[39] L. Seys, W. Widago, F. Verhamme, A. Kleinjan, W. Janssens, G. Joos, K. Bracke, B. Haagmans and G. Brusselle, “DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients,” Clinical Infectious Diseases, vol. 6, no. 66, pp. 45-53, 2018.

[40] B. Alraddadi, J. Watson, A. Almarashi, G. Abdei, A. Turkistani, M. Sadran, A. Housa, M. Almazroa, N. Alraihan, A. Banjar, E. Albalawi, H. Alhindi, A. Choudhry, J. Meiman, M. Paczkowski, A. Curns, A. Mounts, D. Feikin, N. Marano, D. Swerdlow, S. Gerber, R. Hajjeh and T. Madani, “Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Illness in Humans, Saudi Arabia, 2014,” Emerging infectious diseases, vol. 22, no. 1, pp. 49-55, 2016.

[41] U.S. Department of Health and Human Services, The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General, Atlanta, 2006.

[42] World Health Organization, Global Youth Tobacco Survey Factsheets, 2007-2018.

[43] J. DiFranza, A. Masaquel, A. Barrett, A. Colosia and P. Mahadevia, “Systematic literature review assessing tobacco smoke exposure as a risk factor for serious RSV disease among infants and young children,” BMC Pediatrics, vol. 12, no. 81, 2012.

[44] P. Jacob, N. Benowitz, H. Destaillats , L. Gundel, B. Hang, M. Martins-Green, G. Matt, P. Quintana, J. Samet, S. Schick, P. Talbot, N. Aquilina, M. Hovell, J. Mao and T. Whitehead, “Thirdhand Smoke: New Evidence, Challenges, and Future Directions,” Chemical Research in Toxicology, vol. 30, no. 1, pp. 270-294, 2017.

[45] G. Matt, P. Quintana, H. Destaillats, L. Gundel, M. Sleiman, B. Singer, P. Jacob, N. Benowitz, J. Winickoff, V. Rehan, P. Talbot, S. Schick, J. Samet, Y. Wang, B. Hang, M. Martins-Green, J. Pankow and M. Hovell, “Thirdhand tobacco smoke: emerging evidence and arguments for a multidisciplinary research agenda,” Environmental Health Perspectives, vol. 119, no. 9, pp. 1218-26, 2011.

[46] E. Mahabee-Gittens, A. Merianos and G. Matt, “Preliminary evidence that high levels of nicotine on children's hands may contribute to overall tobacco smoke exposure,” Tobacco Control, vol. 27, no. 2, pp. 217-9, 2018.

[47] M. Jawad, S. Jawad, R. Waziry, R. Ballout and E. Akl, “Interventions for waterpipe tobacco smoking prevention and cessation: a systematic review,” Scientific Reports, vol. 6, no. 25872 , 2016.

[48] J. Gotts, S. Jordt, R. McConnell and R. Tarran, “State of the Art Review: What are the respiratory effect of e-cigarettes?,” BMJ , vol. 366, no. l5275, 2019.

[49] World Health Organization, Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems: A Report for the Conference of Parties to the WHO FCTC (FCTC/COP/7/11), 2016.

[50] T. Alzahrani, I. Pena, N. Temesgen and S. Glantz, “Association between electronic cigarette use and myocardial infaction,” American Journal of Preventive Medicine, vol. 55, no. 4, pp. 455-61, 2018.

[51] T. Wills, I. Pagano, R. Williams and E. Tam, “E-cigarette use and respiratory disorderin an adult sample,” Drug and Alcohol Dependence, vol. 194, pp. 363-70, 2019.

[52] World Health Organization, “E-cigarettes: How risky are they?,” 29 January 2020. [Online]. Available: https://www.who.int/news-room/q-a-detail/e-cigarettes-how-risky-are-they. [Accessed 29 March 2020].

[53] World Health Organization, Novel and emerging nicotine and tobacco products: Health effects, research needs and provisional recommended actions for regulators, Cairo, 2020.

[54] U.S. Centers for Disease Control and Prevention, “Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping,” 25 February 2020. [Online]. Available: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html. [Accessed 29 March 2020].

[55] E. Martin, P. Clapp, M. Rebuli, E. Pawlak, E. Glista-Baker, N. Benowitz, R. Fry and I. Jaspers, “E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 311, no. 1, pp. 135-44, 2016.

[56] T. Ghebreyesus, “Progress in beating the tobacco epidemic,” The Lancet, p. Online, 2019.

Additional information

Many countries in the Eastern Mediterranean Region have reported cases of COVID-19. The WHO is actively involved in supporting Member States prepare and respond to the outbreak. Further, regularly updated information about COVID-19 and the WHO’s work can be found here.

For information on countries that took action to strengthen tobacco control in light of COVID-19, please contact the Tobacco Free Initiative, WHO EMRO: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .